[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610954":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":16,"armGroups":17,"interventions":22,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":11,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":11,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Laboratoires Thea","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"global satisfaction of the patient on eyelid comfort after 3 months of Bllephaderm® use, assessed at M4, using a VAS from 0 (unsatisfied) to 10 (very satisfied).",null,"3 months",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","PROSPECTIVE","A total of 30 patients undergoing blepharoplasty or ptosis surgery",[18],{"label":19,"type":11,"description":11,"interventionNames":20},"Group receiving Blephaderm",[21],"Other: Cosmetic: Blephaderm",[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"OTHER","Cosmetic: Blephaderm","Preservative free eyelid cream: Aqua (water), oleyl erucate, trehalose, sodium acrylates copolymer, lecithin, Ophiopogon japonicus root extract, hydrolyzed hyaluronic acid, maltodextrin, tocopherol, sodium hydroxide, phytic acid, Glycine soja (soybean) oil, Helianthus annuus seed oil.",[19],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Medical Affairs Director","CONTACT","+33 4 73 98 14 36","florence.noirt@theapharma.com",[35],{"facility":36,"status":37,"city":38,"state":11,"zip":11,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Pierre-Vincent Jacomet Private Practice","RECRUITING","Paris","France","FR",{"type":42,"coordinates":43},"Point",[44,45],2.3488,48.85341,{"lat":45,"lon":44},[48],{"name":49,"role":31,"phone":11,"phoneExt":11,"email":11},"Pierre-Vincent Jacomet, Dr.",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610954",false,"NCT07234292","Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery","Evaluation of Patient Satisfaction With a New Preservative-free Eyelid Cream as a Complementary Care in Post-eyelid Surgery: The ADMIRE Study","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Patients planning a blepharoplasty or a ptosis surgery in at least one eye.\n* Patient affiliated to a health social security system\n* Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.\n\nExclusion Criteria:\n\nIn terms of population:\n\n* Pregnant or nursing woman or planning a pregnancy during the study.\n* Patient who had been deprived of their freedom by administrative or legal decision\n* Minor patient.\n* Major patient who is under guardianship or who is not able to express his non opposition.\n* Patient suspected to be non-compliant according to the investigator's judgment.\n* Patient enrolled in another clinical trial or which exclusion period is not over.\n\nIn terms of associated pathology\n\n* Patient with a history or active systemic condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk.\n* Patient suffering from a severe or progressive disease.\n* Patient with known or suspected hypersensitivity to one of the components of the product.\n\nRelated to previous or ongoing treatment\n\n* Patient undergoing a topical treatment on the test area or a systemic treatment.\n* Patient under a long-term corticosteroid, NSAID or HIV therapy at the investigator appreciation.\n* Patient under immunosuppressive therapy\n* Patient under bisphosphonate therapy\n* Patient having Type 1 diabetes\n* Patient having atopic or eczema skin\n\nIn terms of lifestyle\n\n* Intensive exposure to sunlight or UV-rays foreseen during the study.\n* Patient planning to change her\u002Fhis life habits during the study.\n* Patient with an excessive consumption of alcohol and\u002For tobacco defined as:\n* an excessive consumption of alcohol: Drinking more than\n* 4 units a day for adult men and more than 2 units a day for adult women,\n* an excessive consumption of tobacco: ≥15-20 Cigarettes Per Day (CPD).","ALL","18 Years",{"count":61,"type":62},30,"ESTIMATED","OBSERVATIONAL","The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis).\n\nThe participant will be asked to use Blephaderm twice a day. The patient satisfaction will be evaluated using a VAS scale.",[66],"Eyelid; Wound","2026-04-28",{"date":69,"type":70},"2026-05-04","ACTUAL",{"date":72,"type":70},"2025-10-30",{"date":74,"type":62},"2026-12-15",{"name":5,"class":6},1]